{"title":"停用胰高血糖素样肽-1 受体激动剂","authors":"Sadiya S. Khan, Chiadi E. Ndumele, Dhruv S. Kazi","doi":"10.1001/jama.2024.22284","DOIUrl":null,"url":null,"abstract":"This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"24 17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists\",\"authors\":\"Sadiya S. Khan, Chiadi E. Ndumele, Dhruv S. Kazi\",\"doi\":\"10.1001/jama.2024.22284\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.\",\"PeriodicalId\":518009,\"journal\":{\"name\":\"JAMA\",\"volume\":\"24 17 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1001/jama.2024.22284\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jama.2024.22284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
本观点讨论了胰高血糖素样肽-1 受体激动剂（GLP-1 RA）对健康的益处；总结了停用 GLP-1 RA 对临床、政策和公平的影响；并呼吁确定和实施改善长期坚持 GLP-1 RA 治疗的策略。
Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
